Description: CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Home Page: www.casipharmaceuticals.com
CASI Technical Analysis
9620 Medical Center Drive
Rockville,
MD
20850
United States
Phone:
240 864 2600
Officers
| Name | Title |
|---|---|
| Dr. Wei-Wu He Ph.D. | Chairman & CEO |
| Dr. Wei Zhang Ph.D. | Pres & Principal Financial Officer |
| Ms. Sara B. Capitelli CPA | VP of Fin. |
| Dr. James E. Goldschmidt Ph.D. | Chief Bus. Devel. Officer |
| Ms. Amanda Cui | VP & Global Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3903 |
| Price-to-Sales TTM: | 0.6618 |
| IPO Date: | 1996-06-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 176 |